Immune Response, Vaccination and Vaccine - Clinical Research Informer

Moderna vaccine safe and spurs immune response in kids, company says

Bio Pharma Dive

OCTOBER 25, 2021

The trial results should allow the company to ask the FDA for approval of its vaccine in younger children, just as Pfizer nears a crucial decision for its shot in 5- to 11-year olds.

Immune Response

Immune Response Vaccination Vaccine Trials

Moderna says its coronavirus vaccine sparks immune response in older people

Bio Pharma Dive

AUGUST 26, 2020

An initial look at the vaccine's effects on the elderly shows those in their 70s had similar responses to those under 55, Moderna told a government panel.

Immune Response

Immune Response Vaccination Vaccine

Novovax’s Omicron-targeting Covid-19 vaccine obtains WHO emergency listing

Pharmaceutical Technology

NOVEMBER 28, 2023

The emergency use listing is based on non-clinical data where the vaccine demonstrated immune responses against variants in SARS-CoV-2.

Immune Response

Immune Response Vaccination Vaccine

New data raise more doubts about Moderna’s flu vaccine

Bio Pharma Dive

APRIL 11, 2023

The shot appears to generate an immune response that matches or exceeds existing vaccines, but investigators aren’t yet sure how well it can prevent illness.

Immune Response

Immune Response Vaccination Vaccine

Self-amplifying mRNA COVID-19 vaccine shows superiority over conventional mRNA vaccine

BioPharma Reporter

OCTOBER 1, 2024

A head-to-head study has revealed that CSL and Arcturus Therapeuticâs self-amplifying mRNA vaccine can maintain a stronger immune response than a conventional mRNA vaccine for up to one year and at a much lower dose.

Vaccination

Vaccination Vaccine Immune Response Development

Gut bacteria could be behind weaker immune responses to COVID-19 vaccine

Medical Xpress

APRIL 20, 2023

Gut bacteria that break down a sugar called fucose could be dampening our immune response to the COVID-19 mRNA vaccine, according to a study led by researchers from the Okinawa Institute of Science and Technology (OIST).

Immune Response

Immune Response Bacteria Vaccination Vaccine

GSK touts co-administration data for RSV, shingles vaccines as narrowed CDC guidance threatens sales

Fierce Pharma

SEPTEMBER 18, 2024

This summer, GSK cut its yearly vaccine sales projection o | In the study, co-administration of GSK's RSV vaccine Arexvy and shingles shot Shingrix elicited non-inferior immune responses compared with separate administration of the vaccines.

Sales

Sales Vaccination Vaccine Immune Response

ImmunityBio gets grant for cross-reactive SARS-COV2 vaccine composition for multiple coronaviruses

Pharmaceutical Technology

APRIL 15, 2024

Discover ImmunityBio Inc's groundbreaking patent for a cross-reactive SARS-CoV2 vaccine targeting multiple variants. Learn how this innovative method boosts immune response and memory cells for enhanced protection.

Immune Response

Immune Response Vaccination Vaccine

Curevac gets grant for pharmaceutical composition for rsv vaccine with modified fusion protein

Pharmaceutical Technology

JUNE 7, 2024

Discover Curevac NV's groundbreaking patent for an mRNA-based RSV vaccine, targeting prophylaxis and treatment. Learn about the innovative pharmaceutical composition and method for stimulating a robust immune response against RSV.

Immune Response

Immune Response Vaccination Vaccine Protein

Intranasal delivery of AstraZeneca COVID-19 vaccine fails to generate strong immune response

BioPharma Reporter

OCTOBER 11, 2022

Intranasal delivery of ChAdOx1 nCoV-19 failed to induce either a consistent mucosal antibody response or a strong systemic immune response, according to results from a Phase 1 clinical trial released today.

Immune Response

Immune Response Vaccination Vaccine Clinical Trials

Pfizer, BioNTech stumble in effort to develop combination flu, COVID shot

Bio Pharma Dive

AUGUST 16, 2024

The vaccine didn’t spur a strong enough immune response against a particular flu strain in a Phase 3 trial, leading the companies to ponder adjustments.

Immune Response

Immune Response Development Vaccination Vaccine

Moderna reveals first study results for seasonal flu vaccine

Bio Pharma Dive

DECEMBER 10, 2021

Data from a small Phase 1 trial showed the biotech's vaccine spurred immune responses to four common strains, although they didn't appear significantly greater than an already available shot from Sanofi.

Immune Response

Immune Response Vaccination Vaccine Trials

Meningitis vaccine comes to the forefront with impressive study results

Pharmaceutical Technology

MAY 25, 2023

A new vaccine developed by the Serum Institute of India to fight meningococcal disease could help eliminate meningitis across Africa. The results from a trial, published in The New England Journal of Medicine , found the vaccine was associated with a strong immune response and good safety profile. for serogroup W to 20.5

Vaccination

Vaccination Vaccine Immune Response Bacteria

Vaxcyte files patent for immunogenic composition for inducing immune responses against gas infections

Pharmaceutical Technology

DECEMBER 21, 2023

This innovative composition induces a protective immune response against Group A Streptococcus (GAS) bacteria, offering potential targets for vaccine development. Discover a groundbreaking immunogenic composition patent that combines GAS polypeptide antigens and polypeptide-polysaccharide conjugates.

Immune Response

Immune Response Bacteria Vaccination Vaccine

Long-term immune response to SARS-CoV-2 mRNA vaccination found to be unaffected by pregnancy

Medical Xpress

DECEMBER 13, 2022

Within a study by investigators at Weill Cornell Medicine and NewYork-Presbyterian, the long-term immune response to SARS-CoV-2 mRNA vaccination was similar in pregnant individuals and non-pregnant individuals of reproductive age.

Immune Response

Immune Response Vaccination Vaccine Medicine

Race for universal flu vaccine ramps up as Osivax kicks off Phase IIa trial

Pharmaceutical Technology

JUNE 16, 2023

France-based biotech company Osivax has thrown its hat into the influenza ring by dosing the first subject with its vaccine candidate OVX836. The Phase IIa trial (NCT05734040) in Australia will see a potential 500 volunteers given OVX836 in combination with quadrivalent influenza vaccines (QIVs).

Vaccination

Vaccination Vaccine Trials Immune Response

Moderna says 'bivalent' booster sparks stronger immune response against omicron

Bio Pharma Dive

JUNE 8, 2022

The biotech claims study results could position its reformulated vaccine as a booster in the fall, though it’s unclear how well the shot can prevent sickness caused by omicron or newer strains of the variant.

Immune Response

Immune Response Vaccination Vaccine

How did pharma develop a vaccine so quickly?

World of DTC Marketing

DECEMBER 29, 2020

OBSERVATION: Biologics can take a long time to develop but COVID vaccines have been in development for almost 50 years and novel approaches were used to develop these vaccines. Vaccines typically take 10 to 15 years to develop, test and release to the public. The coronavirus vaccines, however, took less than a year.

Vaccination

Vaccination Vaccine Development Clinical Trials

Pfizer says coronavirus vaccine is safe and spurs immune response in children

Bio Pharma Dive

SEPTEMBER 20, 2021

The results position Pfizer and BioNTech to seek clearance in children as young as five years old. But the companies haven't yet shared data on a rare heart inflammation associated with their shot that's a concern for regulators.

Immune Response

Immune Response Regulation Vaccination Vaccine

NIH study finds mixing COVID-19 boosters increases immune response

Bio Pharma Dive

OCTOBER 13, 2021

Results suggested Pfizer's and Moderna's vaccines may serve as a more potent booster for those who initially received Johnson & Johnson's shot, although data are limited and preliminary.

Immune Response

Immune Response Vaccination Vaccine

Trim the sugar: New HIV vaccine design improves immune response

Medical Xpress

APRIL 20, 2023

A new HIV vaccine from Scripps Research has shown a significantly improved ability to neutralize the virus in preclinical tests, and it will soon be studied in healthy people who volunteer to participate in clinical trials.

Immune Response

Immune Response Vaccination Vaccine Clinical Trials

Merck and Moderna partner to develop and sell cancer vaccine

Pharmaceutical Technology

OCTOBER 14, 2022

German pharmaceutical firm Merck has extended its partnership with Moderna to jointly develop and sell mRNA-4157/V940, an investigational personalised cancer vaccine (PCV). They subsequently expanded the collaboration to include the development of antigen mRNA cancer vaccines in 2018.

Vaccination

Vaccination Vaccine Development Immune Response

XtalPi and CK Life Sciences to develop AI-driven tumour vaccine R&D platform

Pharmaceutical Technology

NOVEMBER 25, 2022

XtalPi has entered a strategic partnership with CK Life Sciences for artificial intelligence (AI)-driven tumour vaccine research and development (R&D). Under the collaboration, the companies will utilise their capabilities to co-develop a new AI tumour vaccine R&D platform.

Life Science

Life Science Vaccination Vaccine Development

HIV vaccines suffer setbacks but new approaches could turn the tide

Pharmaceutical Technology

FEBRUARY 3, 2023

Only a few weeks into the new year, the prospect of getting a successful advanced HIV vaccine shrank after the discontinuation of yet another late-stage trial. On January 18, Janssen, a Johnson & Johnson (J&J) subsidiary, stated that its vaccine was not effective in preventing HIV infections.

Vaccination

Vaccination Vaccine Antibody Trials

Team studies immune response, proteins in blood of young adults who develop rare complication after COVID vaccination

Medical Xpress

JANUARY 4, 2023

Myocarditis, a condition in which the heart muscle becomes inflamed, is a rare complication that can occur after mRNA COVID vaccination. It's estimated that roughly 18 cases occur in every 1 million vaccine doses administered, making it so rare that it is challenging to find cases to investigate.

Immune Response

Immune Response Protein Vaccination Vaccine

GreenLight and US NIH partner to develop Covid-19 vaccine for variants

Pharmaceutical Technology

AUGUST 1, 2022

GreenLight Biosciences has entered a partnership with the US National Institutes of Health (NIH) for the development of Covid-19 vaccines, which offer broader protection against new variants and with durable effects. They intend to develop vaccines that provide lasting immune responses compared to existing vaccines.

Vaccination

Vaccination Vaccine Development RNA

RVAC and University of Pennsylvania to develop mRNA vaccines

Pharmaceutical Technology

MARCH 20, 2023

RVAC Medicines has announced a research collaboration with the University of Pennsylvania (Penn) for the discovery and development of mRNA vaccines. The mRNA vaccine candidates will help reduce the chances of autoimmune responses that might lead to allergic conditions or serious autoimmune diseases.

Vaccination

Vaccination Vaccine Development Allergies

UK MHRA grants authorisation for Moderna’s Covid-19 booster vaccine

Pharmaceutical Technology

AUGUST 15, 2022

The UK Medicines and Healthcare products Regulatory Agency (MHRA) has granted conditional authorisation for Moderna ’s Covid-19 booster vaccine, mRNA-1273.214 (Spikevax Bivalent Original/Omicron), for use in adults aged 18 years and above. It comprises mRNA-1273 (Spikevax) and a vaccine candidate that acts on the SARS-CoV-2 virus’ BA.1

Vaccination

Vaccination Vaccine Immune Response Clinical Trials

Study: CureVac’s COVID-19 Vaccine Produces Immune Responses in Healthy Volunteers

BioSpace

NOVEMBER 1, 2020

Newly announced results of a Phase I dose-escalation study show CureVac’s COVID-19 vaccine candidate, CVnCoV, generates noticeable immune responses in healthy volunteers.

Immune Response

Immune Response Vaccination Vaccine

Moderna, with new data, to seek clearance for COVID-19 vaccine in young children

Bio Pharma Dive

MARCH 23, 2022

Study results showed two shots of Moderna's vaccine led to similar immune responses as has been observed in young adults, although protection versus omicron was modest.

Immune Response

Immune Response Vaccination Vaccine

Sanofi-GSK COVID-19 Vaccine Hits Snag With Insufficient Immune Response in 50+ Population

BioSpace

DECEMBER 10, 2020

The COVID-19 vaccine candidate developed by Sanofi and GlaxoSmithKline hit a snag that will delay the launch of a Phase III study due to an insufficient immune response in older trial patients.

Immune Response

Immune Response Vaccination Vaccine Trials

AstraZeneca's COVID-19 Vaccine Boosts Immune Response in Older, Younger Adults

BioSpace

OCTOBER 26, 2020

FDA greenlit the restart of AstraZeneca’s Phase III COVID-19 vaccine trial, the company said the preventative medication boosts immune responses in older and younger adults against the novel coronavirus. Days after the U.S.

Immune Response

Immune Response Vaccination Vaccine Trials

Moderna data supports use of omicron booster over original vaccine

Bio Pharma Dive

NOVEMBER 14, 2022

New results show the two-pronged booster the FDA cleared in August sparks a stronger immune response against omicron and its subvariants than Moderna’s original shot.

Immune Response

Immune Response Vaccination Vaccine

Early data shows Russia’s Sputnik V COVID-19 vaccine produces immune response

pharmaphorum

SEPTEMBER 7, 2020

A trial of Russia’s Sputnik V coronavirus vaccine has shown the jab produces an immune response, although the study was too small to produce conclusive findings, particularly on safety. The vaccine also produced a T-cell response within 28 days, a secondary outcome.

Immune Response

Immune Response Vaccination Vaccine Trials

GSK enters agreement with Canada for influenza vaccines

Pharmaceutical Technology

JULY 18, 2022

GlaxoSmithKline (GSK) has signed an agreement with the Government of Canada for pandemic and seasonal influenza vaccines to aid in protecting adults and children in the country. The company intends to supply both vaccines from its 230,000ft² Sainte-Foy facility in Quebec. .

Vaccination

Vaccination Vaccine Immune Response Clinical Trials

Vaxcyte's pneumococcal vaccine win points to Prevnar battle

pharmaphorum

SEPTEMBER 3, 2024

Vaxcyte's new pneumococcal vaccine may only have phase 1/2 results behind it, but analysts are already predicting it could be a major competitor to rival shots from Pfizer and MSD.Just-reported data from that study has shown that Vaxcyte's VAX-31 shot was able to stimulate a strong immune response against all 31 serotypes of Streptococcus pneumoniae (..)

Vaccination

Vaccination Vaccine Immune Response

EMA approves Bavarian Nordic’s mpox vaccine for teenagers

Pharmaceutical Technology

SEPTEMBER 20, 2024

Data showed non-inferiority of immune response between adults and adolescents with Imvanex.

Immune Response

Immune Response Vaccination Vaccine

Organoids shown to speed glycoengineered vaccine development

Medical Xpress

APRIL 12, 2023

Testing the efficacy of a vaccine candidate is typically a long process, with the immune response of an animal model taking around two months.

Vaccination

Vaccination Vaccine Immune Response Development

Merck, chasing Pfizer, claims study success for new pneumonia vaccine

Bio Pharma Dive

JULY 27, 2023

The pharma said its latest shot, which covers 21 strains of bacteria, cleared two Phase 3 trials and in some cases spurred a stronger immune response than Pfizer’s Prevnar 20.

Immune Response

Immune Response Bacteria Vaccination Vaccine

Intravacc gets NIAID contract for intranasal gonorrhoea vaccine development

Pharmaceutical Technology

OCTOBER 6, 2022

from the US National Institutes of Health (NIH) unit National Institute of Allergy and Infectious Diseases (NIAID) to develop a prophylactic intranasal vaccine against Neisseria gonorrhoeae (NG). Leveraging its outer membrane vesicles (OMV) platform technology, Intravacc will develop the vaccine.

Vaccination

Vaccination Vaccine Development Bacterium

Immunomodulators boost vaccine response and reduce inflammation, finds study

Medical Xpress

APRIL 5, 2023

Adjuvants—ingredients that help boost the immune response in vaccines—have been used in vaccines for decades. But inducing a stronger immune response can result in more unwanted side effects, like swelling at the injection site or fever and body aches.

Immune Response

Immune Response Vaccination Vaccine

HDT Bio receives Emergency Use Approval for Covid-19 vaccine in India

Pharmaceutical Technology

JUNE 30, 2022

HDT Bio has received Emergency Use Approval from Indian regulators for its Covid-19 vaccine, Gemcovac. The vaccine leverages self-amplifying RNA (saRNA), which can replicate itself after administration and could be effective at very low doses. HDT Bio CEO Steve Reed said: “Our saRNA vaccine is a game-changer.

Vaccination

Vaccination Vaccine Clinical Trials Clinical Trials

South Korea authorises Novavax Covid-19 vaccine as booster dose

Pharmaceutical Technology

JANUARY 19, 2023

The Korean Ministry of Food and Drug Safety (KMFDS) has granted expanded approval to Novavax partner SK bioscience for the Covid-19 vaccine, Nuvaxovid (NVX-CoV2373), for use as a booster dose in adults aged 18 and above. Nuvaxovid is a protein-based vaccine created from the genetic sequence of the initial SARS-CoV-2 virus strain.

Vaccination

Vaccination Vaccine Immune Response Protein

Health Canada grants expanded authorisation for Novavax’s Covid-19 vaccine

Pharmaceutical Technology

NOVEMBER 20, 2022

Health Canada has granted expanded authorisation for Novavax ’s Covid-19 vaccine (Recombinant protein, Adjuvanted) [Nuvaxovid; NVX-CoV2373] as a homologous booster for usage in adults aged 18 and above. The vaccine is indicated for active immunisation to prevent the disease.

Vaccination

Vaccination Vaccine Immune Response Protein

Moderna vaccine safe and spurs immune response in kids, company says

Moderna says its coronavirus vaccine sparks immune response in older people

Trending Sources

Novovax’s Omicron-targeting Covid-19 vaccine obtains WHO emergency listing

New data raise more doubts about Moderna’s flu vaccine

Self-amplifying mRNA COVID-19 vaccine shows superiority over conventional mRNA vaccine

Gut bacteria could be behind weaker immune responses to COVID-19 vaccine

GSK touts co-administration data for RSV, shingles vaccines as narrowed CDC guidance threatens sales

ImmunityBio gets grant for cross-reactive SARS-COV2 vaccine composition for multiple coronaviruses

Curevac gets grant for pharmaceutical composition for rsv vaccine with modified fusion protein

Intranasal delivery of AstraZeneca COVID-19 vaccine fails to generate strong immune response

Pfizer, BioNTech stumble in effort to develop combination flu, COVID shot

Moderna reveals first study results for seasonal flu vaccine

Meningitis vaccine comes to the forefront with impressive study results

Vaxcyte files patent for immunogenic composition for inducing immune responses against gas infections

Long-term immune response to SARS-CoV-2 mRNA vaccination found to be unaffected by pregnancy

Race for universal flu vaccine ramps up as Osivax kicks off Phase IIa trial

Moderna says 'bivalent' booster sparks stronger immune response against omicron

How did pharma develop a vaccine so quickly?

Pfizer says coronavirus vaccine is safe and spurs immune response in children

NIH study finds mixing COVID-19 boosters increases immune response

Trim the sugar: New HIV vaccine design improves immune response

Merck and Moderna partner to develop and sell cancer vaccine

XtalPi and CK Life Sciences to develop AI-driven tumour vaccine R&D platform

HIV vaccines suffer setbacks but new approaches could turn the tide

Team studies immune response, proteins in blood of young adults who develop rare complication after COVID vaccination

GreenLight and US NIH partner to develop Covid-19 vaccine for variants

RVAC and University of Pennsylvania to develop mRNA vaccines

UK MHRA grants authorisation for Moderna’s Covid-19 booster vaccine

Study: CureVac’s COVID-19 Vaccine Produces Immune Responses in Healthy Volunteers

Moderna, with new data, to seek clearance for COVID-19 vaccine in young children

Sanofi-GSK COVID-19 Vaccine Hits Snag With Insufficient Immune Response in 50+ Population

AstraZeneca's COVID-19 Vaccine Boosts Immune Response in Older, Younger Adults

Moderna data supports use of omicron booster over original vaccine

Early data shows Russia’s Sputnik V COVID-19 vaccine produces immune response

GSK enters agreement with Canada for influenza vaccines

Vaxcyte's pneumococcal vaccine win points to Prevnar battle

EMA approves Bavarian Nordic’s mpox vaccine for teenagers

Organoids shown to speed glycoengineered vaccine development

Merck, chasing Pfizer, claims study success for new pneumonia vaccine

Intravacc gets NIAID contract for intranasal gonorrhoea vaccine development

Immunomodulators boost vaccine response and reduce inflammation, finds study

HDT Bio receives Emergency Use Approval for Covid-19 vaccine in India

South Korea authorises Novavax Covid-19 vaccine as booster dose

Health Canada grants expanded authorisation for Novavax’s Covid-19 vaccine

Stay Connected